<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183077</url>
  </required_header>
  <id_info>
    <org_study_id>107.214</org_study_id>
    <nct_id>NCT02183077</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects</brief_title>
  <official_title>Pharmacokinetics and Tolerability of 2 x 15 mg Meloxicam (2 x 0.3 g Topical Gel) Over 7 Days Compared to 7.5 mg Meloxicam Tablet (Single Oral Dose) in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to gain information on the percutaneous absorption of meloxicam after administration of
      a topical gel over 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <primary_completion_date type="Actual">November 1998</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of plasma concentration-time course after topical dose</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the ratio AUCss topical/AUC0-∞ oral</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of the analyte in plasma (Tmax)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total area under the plasma drug concentration time curve (AUC) from time of administration to the time of the last quantifiable drug concentration (AUC0-t)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t½)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination rate constant</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance of the analyte in plasma following extravascular administration (CL/F)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution of the analyte during the terminal phase (Vz/F)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRTtot)</measure>
    <time_frame>up to 96 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excretion of metabolites in urine</measure>
    <time_frame>0-24 hours after oral administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose concentration of the analyte in plasma at steady state immediately before administration of the next dose (Cpre,ss)</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmin,ss)</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ (Cmax,ss)</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total area under the plasma drug concentration time curve (AUC) during a steady state interval (AUCss)</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of the analyte in plasma (t½)</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent terminal elimination rate constant</measure>
    <time_frame>up to 264 hours after first topical administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of adverse events</measure>
    <time_frame>up to 24 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of local and systemic tolerability</measure>
    <time_frame>up to 24 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Meloxicam gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam gel</intervention_name>
    <arm_group_label>Meloxicam gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam tablet</intervention_name>
    <arm_group_label>Meloxicam tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects as determined by results of screening

          -  Signed written informed consent in accordance with Good Clinical Practice and local
             legislation

          -  Age &gt;= 18 and &lt;= 50 years

          -  Broca &gt;= -20% and &lt;= + 20 %

        Exclusion Criteria:

          -  Any findings of the medical examination (including blood pressure, pulse rate and
             electrocardiogram) deviating from normal and of clinical relevance

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of the gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  Hypersensitivity to meloxicam and any of the excipients or non-steroidal antirheumatic
             agents

          -  Intake of drugs with a long half-life (&gt;24 hours) (&lt;= 1 month prior to administration
             or during the trial)

          -  Use of any drugs which might influence the results of the trial (&lt;= 10 days prior to
             administration or during the trial)

          -  Participation in another trial with an investigational drug (&lt;= 2 months prior to
             administration or during the trial)

          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt;3 pipes/day)

          -  Inability to refrain from smoking on study days

          -  Known alcohol abuse

          -  Known drug abuse

          -  Blood donation (&lt;= 1 months prior to administration)

          -  Excessive physical activities (&lt;= 5 days prior to administration)

          -  History of hemorrhagic diatheses

          -  History of gastrointestinal ulcer, perforation or bleeding

          -  History of bronchial asthma

          -  Any laboratory value outside the normal range of clinical relevance

          -  History of dermatological diseases

          -  Skin disease and/or skin lesions at the site of planned application

        For female subjects:

          -  Pregnancy

          -  Positive pregnancy test

          -  Breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

